CA-CROWN-BIOSCIENCE
Crown Bioscience , a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005025/en/
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development.
Building on the company’s continued growth, three new roles have been created within the commercial team and will report to Mr. Prosser. Alex Slater, who joined the company last year, has taken on added responsibility for APAC business development as Vice President of Global Business Development; Dr. Jonny McMichael has been appointed to Vice President of Client Experience and Enablement; and Dr. Achim Quandt has joined the company as Executive Director of Product Management.
“Crown Bioscience has grown significantly in recent years, consistently exceeding its annual growth target, and in FY21 we were delighted to record bookings growth of over 40%,” said Armin Spura, CEO. “With these changes announced today and under Michael's continued leadership, we are confident we are putting in place a commercial team that optimally positions Crown Bioscience for our next phase of growth.”
Michael Prosser, CBO, stated: “It’s an honor to be asked to lead the next stage in Crown Bioscience’s commercial growth. Our success to date is directly attributable to our relentless focus on customer experience, product innovation, and setting new industry-leading quality standards, and I’m excited to be working closely with the new team and structure as we strive to continuously improve in all these areas.”
The company added more than four hundred new customers in FY21, and to meet increased customer demand, has accelerated investments in its global footprint, with renovations now complete in APAC laboratories, and notably the formation of a joint venture with sister company MBL in Japan. In Europe and the United States, parallel investments are also planned for site expansions and strategic acquisitions.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 09:30:00 CEST | Press release
The PROCLIPI study, one of the largest studies to date in cutaneous T-cell lymphoma (CTCL), is a prospective, observational, multicentre international registry spanning 19 countries and includes over 2,000 patients, collects data to develop prognostic indices for CTCL1An analysis of 371 patients observed meaningful overall survival (OS) benefit for patients with advanced mycosis fungoides (MF) and Sézary syndrome (SS) treated with POTELIGEO (mogamulizumab)1,2,3Findings align with earlier survival signals and highlight how global collaboration can generate meaningful evidence in rare conditions such as MF and SS4,5Results were presented at this year’s European Organisation for Research and Treatment of Cancer - Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting in Athens, Greece2 Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingh
World First: H-UKR 0% Clinker Cement Obtains Technical Assessment (ATec) for Wind Turbine Foundations22.10.2025 08:00:00 CEST | Press release
Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, today announces that it has obtained a Technical Assessment (ATec) validating the use of its H-UKR decarbonized cement for wind turbine foundations. This unprecedented recognition, a world first for a 0% clinker cement, certifies that the H-UKR solution meets the highest standards of sustainability, safety, and performance for particularly rigorous applications such as wind power. A strategic step towards new markets This certification marks another key milestone for Hoffmann Green, enabling it to further accelerate its growth in the renewable energy market from 2026 and beyond. Obtaining this ATec certification paves the way for new commercial opportunities in this sector, strengthening its insurability with project owners
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors22.10.2025 02:25:00 CEST | Press release
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ProgramTakeda to Lead IBI363 Global Co-Development and U.S. Co-Commercialization and Will Have Exclusive Commercialization Rights Outside the U.S. and Greater China; IBI363 is a Late-Stage Bispecific Antibody Fusion Protein Being Evaluated in Non-Small Cell Lung and Colorectal Cancers, with Potential in Additional Solid Tumor TypesTakeda to Receive Exclusive Rights for IBI343 Outside of Greater China; IBI343 is a Late-Stage Antibody-Drug Conjugate Being Evaluated in Gastric and Pancreatic CancersTakeda Intends to Establish Manufacturing for These Investigational Medicines in the U.S. Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage o
YES Selected to Deliver Full Portfolio of Advanced Packaging Tools for Glass Panel AI and HPC Applications by a Leading AI Infrastructure Supplier21.10.2025 21:16:00 CEST | Press release
Yield Engineering Systems (YES), a leading provider of advanced process equipment for AI and high-performance computing (HPC) semiconductor applications, today announced that it has received multiple tool orders from a global leader in AI infrastructure solutions. The orders span YES’s portfolio of Dry and Wet process systems and will support panel-level manufacturing on glass substrates for next-generation data center and HPC packaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020459437/en/ YES VertaCure, VertaPrime, VeroFlex, TersOra, and SURE systems. The systems will be deployed in advanced packaging lines dedicated to hyperscale AI workloads, including training, inference, networking, and co-packaged optics. This award marks a significant milestone in the industry's shift toward glass-based 2.5D and 3D packaging as system performance, density, and thermal requirements escalate. YES will supply a full suite of s
Esri and UNFPA Extend Strategic Partnership to Support 2030 Census Round21.10.2025 21:09:00 CEST | Press release
Collaboration Strengthens Census Through Location-Enabled Data Sharing Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic information system (GIS) technology into all phases of census work. By leveraging GIS, national statistics and census offices will gain access to more authoritative, location-enabled data and faster, more efficient methods of planning, collection, and dissemination. “National census projects can often involve mapping an entire country,” said Linda Peters, Esri global business development manager. “GIS is becoming crucial for every step of a census but deploying it is new to many national statistical offices. We are happy to provide the resources that can enable this large-scale feat of authoritative data collection an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom